PCSK9 and atherosclerosis: However, for patients at very high risk, including those with ASCVD, for whom the lowest LDL-C goals are recommended, the use of the combination therapy of an optimised statin, ezetimibe and a PCSK9 inhibitor would result in approximately 90% of patients achieving their risk-based LDL-C goals.